Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Endocrine Tumor Committee
Director: Dr. Julien Hadoux
Multidisciplinary expertise in endocrine cancers
The Endocrine Tumors Committee brings together specialists involved in the diagnosis and treatment of thyroid and adrenal gland cancers, as well as neuroendocrine tumors. These diseases can develop in various organs and exhibit a wide range of behaviors. Some produce hormones, which requires specific evaluation and management.
Each case is discussed in a multidisciplinary setting to tailor the treatment strategy to the nature of the tumor, its degree of differentiation, its extent, its potential hormonal activity, and the patient’s condition.
Types of Cancer Treated
- Thyroid Cancers:
Differentiated, medullary, and anaplastic cancers, particularly advanced or refractory forms - Neuroendocrine carcinomas:
Poorly differentiated forms, which are generally more aggressive and require a specific treatment strategy - Paragangliomas:
Rare tumors related to pheochromocytomas, developing outside the adrenal gland - Thoracic neuroendocrine tumors
Tumors that can develop, in particular, in the lung or thymus - Well-differentiated neuroendocrine tumors
Neuroendocrine tumors, sometimes called carcinoid tumors, that can develop in several organs - Adrenal tumors:
Adrenocortical tumors, pheochromocytomas, and other adrenal tumors - Gastrointestinal neuroendocrine tumors:
Tumors of the gastrointestinal tract or pancreas - Other rare endocrine cancers:
Conditions requiring specialized diagnostic and therapeutic expertise
An expert diagnosis to guide treatment
Pathological analysis distinguishes, in particular, well-differentiated neuroendocrine tumors from poorly differentiated carcinomas, which have different courses of disease and treatment regimens.
Morphological imaging, functional imaging, and nuclear medicine make it possible to pinpoint the locations of the disease and, depending on the case, the targets that can be addressed by certain treatments.
Some endocrine tumors may be associated with a genetic predisposition. An oncogenetics consultation may be recommended when warranted.
The committee members
Dr. Julien Hadoux, Committee Chair
Dr. Eric Baudin
Dr. Livia Lamartina
Dr. Sophie Moog
Dr. Désirée Deandreis
Dr. Camilo Garcia
Dr. Tarek Kamoun
Dr. Khalil Trabelsi
Dr. Dana Hartl
Dr. Ingrid Breuskin
Dr. Matthieu Faron
Dr. Leonor Benhaim
Dr. Maximiliano Gelli
Dr. Marie Attard
Dr. Sophie Bidault
Dr. Elisabeth Girard
Dr. Gabriel Garcia
Dr. David Planchard, Thoracic Oncology
Prof. Michel Ducreux, Dr. David Malka, Dr. Valérie Boige, Dr. Pascal Burtin, Gastrointestinal Oncology
Dr. Jérôme Durand-Labrunie
Dr. Pascal Burtin, Endoscopic Ultrasound
Dr. Dominique Fabre
Prof. Elie Fadel
Dr. Olaf Mercier
Dr. Sacha Mussot
Marie-Lannelongue Hospital
Dr. Sylvain Briand
Bicêtre Hospital, AP-HP
Research and Innovation in Endocrine Cancers
The committee's physicians conduct and coordinate national and international clinical trials focused on thyroid, neuroendocrine, and adrenal cancers. This research focuses in particular on rare, advanced, or treatment-resistant forms of these cancers.
Identify biological characteristics that can help predict the course of the disease or the likelihood of response to treatment.
Evaluate drugs that target a molecular abnormality or a mechanism on which the tumor depends.
To study the role of treatments that activate the immune system in certain advanced forms of endocrine cancers.
To better characterize tumors and their resistance mechanisms in order to tailor treatment strategies and drug combinations.
Dr. Julien Hadoux coordinates clinical trials and translational research studies. He also serves as the national coordinator of the ENDOCAN network, which focuses on rare endocrine cancers, and participates in French and European groups that help develop treatment guidelines.